Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

586
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
586
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.5K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

546
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
546
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

3.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.9K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

4.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.4K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

90
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
90

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bringing nutritional ketosis to the table as an option for healing the pediatric brain.

Frontiers in nutrition·2024
Same author

Excitatory Dysfunction Drives Network and Calcium Handling Deficits in 16p11.2 Duplication Schizophrenia Induced Pluripotent Stem Cell-Derived Neurons.

Biological psychiatry·2022
Same author

Monoallelic and biallelic mutations in RELN underlie a graded series of neurodevelopmental disorders.

Brain : a journal of neurology·2022
Same author

K<sub>Na</sub>1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons.

Neurobiology of disease·2022
Same author

Loss-of-function variants in TIAM1 are associated with developmental delay, intellectual disability, and seizures.

American journal of human genetics·2022
Same author

Pearls & Oy-sters: When Genetic Generalized Epilepsy Becomes Progressive.

Neurology·2020

Related Experiment Video

Updated: Nov 24, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

87.0K

Hypoglycemia in Infants and Effect on Neurodevelopment.

Bridget R McGowan1,2, Tracy S Gertler1,2

  • 1Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.

Pediatric Neurology Briefs
|December 23, 2020
PubMed
Summary

This study compared two glucose thresholds for treating neonatal hypoglycemia, finding that a lower threshold (36 mg/dL) did not worsen developmental outcomes compared to the traditional 47 mg/dL threshold.

Keywords:
Blood GlucoseChild DevelopmentHypoglycemiaInfantNewborn

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.6K
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

305

Related Experiment Videos

Last Updated: Nov 24, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

87.0K
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.6K
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

305

Area of Science:

  • Neonatal Medicine
  • Pediatric Endocrinology
  • Clinical Trials

Background:

  • Neonatal hypoglycemia is common and can impact neurodevelopment.
  • Current treatment guidelines vary regarding glucose thresholds.

Purpose of the Study:

  • To compare developmental outcomes in infants treated for neonatal hypoglycemia using two different glucose thresholds.
  • To evaluate the safety and efficacy of a lower glucose threshold for intervention.

Main Methods:

  • Prospective, randomized treatment trial involving multiple institutions.
  • Comparison of a 47 mg/dL glucose threshold versus a 36 mg/dL threshold for intervention.
  • Assessment of developmental outcomes post-treatment.

Main Results:

  • The study aimed to determine if a lower glucose threshold impacts developmental outcomes.
  • Results will indicate whether the 36 mg/dL threshold is non-inferior to the 47 mg/dL threshold.

Conclusions:

  • Findings will inform clinical practice guidelines for managing neonatal hypoglycemia.
  • Establishing an optimal glucose threshold can improve infant neurodevelopmental trajectories.